<DOC>
	<DOC>NCT02519400</DOC>
	<brief_summary>A total of 24 healthy Korean male subjects will receive a single oral dose of amitriptyline, 25 mg. Subjects will be enrolled in this study based on their cytochrome P450 2D6 and cytochrome P450 2C19 genotypes, and serial blood sampling will be done for plasma concentrations of amitriptyline, nortriptyline, and their metabolites. Various pharmacodynamic markers related to the adverse event of amitriptyline will be measured serially during the study.</brief_summary>
	<brief_title>A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
	<criteria>Healthy male volunteer, age 19~45 years The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 28 kg/m2 Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial. Voluntarily signed the informed consent form Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study History of relevant drug allergies or clinically significant hypersensitivity reaction. Smoked more than 10 cigarettes a day for past 3 months Not eligible due to other reasons including laboratory results</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>amitriptyline</keyword>
	<keyword>cyp2d6</keyword>
	<keyword>cyp2c19</keyword>
</DOC>